| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
With IC50 values of 100 and >200 µM, respectively, marein (0-1000 µM; 24 h) suppresses TNFα-induced NF-κB activation as well as HDAC activity [1]. In HepG2 cells, marein (1.25–40 μM; 24 hours) increases the absorption of glucose [2]. Marein (5–10 μM; 24 hours) elevates the amount of liver glycogen, decreases the expression of G6Pase and PEPCK in HepG2 cells, and facilitates the transfer of GLUT1 from intercellular vesicles to the plasma membrane [2]. Marein (5–10 μM; 24 hours) increases the absorption of 2-NBDG and is inhibited by STO-609 and Compound C, an AMPK inhibitor [2]. In PC12 cells, marein (0–40 μM; 24 hours) alters the cytotoxicity of MG [3].
|
|---|---|
| Cell Assay |
Western Blot Analysis [2]
Cell Types: HepG2 cell line Tested Concentrations: 5 and 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: The translocation of GLUT1 to the plasma membrane was increased and the phosphorylation levels of AS160 and GSK-3β were diminished in HepG2 cells. Western Blot Analysis[2] Cell Types: HepG2 Cell Line Tested Concentrations: 10 μM Incubation Duration: 0-10 hrs (hours) Experimental Results: Time- and dose-dependent induction of AMPK and Akt phosphorylation in HepG2 cells. Cell viability assay [3] Cell Types: PC12 Cell Line Tested Concentrations: 0-40 μM Incubation Duration: 24 hrs (hours) Experimental Results: Prevents MG-induced loss of PC12 cell viability. Apoptosis analysis[3] Cell Types: PC12 Cell Line Tested Concentrations: 5-10 μM Incubation Duration: 30 minutes Experimental Results: Protection of PC12 cells from MG-induced apoptosis. Western Blot Analysis[3] Cell Types: PC12 Cell Line Tested Concentrations: 5-10 μM Incubation Duration: 30 minutes Experimental Results: Increased Phospho-AMPKα (Thr172) in PC12 cells. |
| References | |
| Additional Infomation |
Marein is a member of flavonoids and a glycoside.
Marein has been reported in Abies pindrow, Viguiera dentata, and other organisms with data available. |
| Molecular Formula |
C21H22O11
|
|---|---|
| Molecular Weight |
450.39278
|
| Exact Mass |
450.116
|
| CAS # |
535-96-6
|
| PubChem CID |
6441269
|
| Appearance |
Yellow to orange solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
835.4±65.0 °C at 760 mmHg
|
| Melting Point |
197-202ºC
|
| Flash Point |
293.5±27.8 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.751
|
| LogP |
-0.18
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
32
|
| Complexity |
658
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC(=C(C=C1/C=C/C(=O)C2=C(C(=C(C=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O)O
|
| InChi Key |
XGEYXJDOVMEJNG-HTFDPZBKSA-N
|
| InChi Code |
InChI=1S/C21H22O11/c22-8-15-18(28)19(29)20(30)21(32-15)31-14-6-3-10(16(26)17(14)27)11(23)4-1-9-2-5-12(24)13(25)7-9/h1-7,15,18-22,24-30H,8H2/b4-1+/t15-,18-,19+,20-,21-/m1/s1
|
| Chemical Name |
(E)-3-(3,4-dihydroxyphenyl)-1-[2,3-dihydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~55.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: 2.5 mg/mL (5.55 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2203 mL | 11.1015 mL | 22.2030 mL | |
| 5 mM | 0.4441 mL | 2.2203 mL | 4.4406 mL | |
| 10 mM | 0.2220 mL | 1.1101 mL | 2.2203 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
